Investigational drug · Phase 2
QCZ484
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hypertension (HTN), Hypertension, Hypercholesterolaemia.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
4
Any phase or sponsor naming "QCZ484"
First trial start
2025
Mar 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "QCZ484", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hypertension (HTN)
- Hypertension
- Hypercholesterolaemia
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "QCZ484" as an intervention, largest first.
- A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive PatientsPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06857955 · 396 participants · Start Mar 26, 2025 · Primary completion Sep 17, 2026
Drug: QCZ484 · For: Hypertension
Sites: Andalusia, Alabama; Huntsville, Alabama; Saraland, Alabama · 72 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07543120 · 323 participants (planned) · Start May 7, 2026 · Primary completion May 7, 2031
Drug: QCZ484 · For: Hypertension (HTN)
Sites: Andalusia, Alabama; Tucson, Arizona; Garden Grove, California · 46 sites in all
- A Study to Evaluate the Pharmacodynamics of a Combination of QCZ484 and Inclisiran in Participants With Hypertension and Concomitant HypercholesterolemiaPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07610278 · 120 participants (planned) · Start May 29, 2026 · Primary completion Apr 28, 2027
Drug: QCZ484; Inclisiran and 2 more · For: Hypercholesterolaemia
Sites: Foley, Alabama; Saraland, Alabama; Lincoln, California · 29 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06905327 · 56 participants · Start Mar 8, 2023 · Primary completion Sep 25, 2024
Drug: QCZ484; Placebo · For: Mild Hypertension
Sites: Herston, Australia; Morayfield, Australia; Adelaide, Australia · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Hypertension (HTN)
- of QLS1410Phase 22 trials
Qilu Pharmaceutical Co., Ltd. · Hypertension (HTN), Uncontrolled Hypertension
- SPC1001Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5002Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5003Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
- SPC5004Phase 21 trial
Shin Poong Pharmaceutical Co. Ltd. · Hypertension (HTN), NYHA Class III Heart Failure, NYHA Class IV Heart Failure
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.